BACKGROUND: Arteriovenous malformations (AVMs) of the brain and face present unique challenges for clinicians. Cerebral AVMs may induce hemorrhage or form aneurysms, while facial AVMs can cause significant disfigurement and pain. Moreover, facial AVMs often draw blood supply from arteries providing critical blood flow to other important structures of the head which may make them impossible to treat curatively. Medical adjuvants may be an important consideration in the management of these patients. SUMMARY: We conducted a systematic review of the literature to identify other instances of molecular target of rapamycin (mTOR) inhibitors used as medical adjuvants for the treatment of cranial and facial AVMs. We also present 2 cases from our own institution where patients were treated with partial embolization, followed by adjuvant therapy with rapamycin. After screening a total of 75 articles, 7 were identified which described use of rapamycin in the treatment of inoperable cranial or facial AVM. In total, 21 cases were reviewed. The median treatment duration was 12 months (3-24.5 months), and the highest recorded dose was 3.5 mg/m2. 76.2% of patients demonstrated at least a partial response to rapamycin therapy. In 2 patients treated at our institution, symptomatic and radiographic improvement were noted 6 months after initiation of therapy. Key Messages: Early results have been encouraging in a small number of patients with inoperable AVM of the head and face treated with mTOR inhibitors. Further study of medical adjuvants such as rapamycin may be worthwhile.
BACKGROUND: Arteriovenous malformations (AVMs) of the brain and face present unique challenges for clinicians. Cerebral AVMs may induce hemorrhage or form aneurysms, while facial AVMs can cause significant disfigurement and pain. Moreover, facial AVMs often draw blood supply from arteries providing critical blood flow to other important structures of the head which may make them impossible to treat curatively. Medical adjuvants may be an important consideration in the management of these patients. SUMMARY: We conducted a systematic review of the literature to identify other instances of molecular target of rapamycin (mTOR) inhibitors used as medical adjuvants for the treatment of cranial and facial AVMs. We also present 2 cases from our own institution where patients were treated with partial embolization, followed by adjuvant therapy with rapamycin. After screening a total of 75 articles, 7 were identified which described use of rapamycin in the treatment of inoperable cranial or facial AVM. In total, 21 cases were reviewed. The median treatment duration was 12 months (3-24.5 months), and the highest recorded dose was 3.5 mg/m2. 76.2% of patients demonstrated at least a partial response to rapamycin therapy. In 2 patients treated at our institution, symptomatic and radiographic improvement were noted 6 months after initiation of therapy. Key Messages: Early results have been encouraging in a small number of patients with inoperable AVM of the head and face treated with mTOR inhibitors. Further study of medical adjuvants such as rapamycin may be worthwhile.
Authors: Katarzyna Switon; Katarzyna Kotulska; Aleksandra Janusz-Kaminska; Justyna Zmorzynska; Jacek Jaworski Journal: Neuroscience Date: 2016-11-23 Impact factor: 3.590
Authors: Malcolm Pyles Chelliah; Huy M Do; Zachary Zinn; Viraat Patel; Michael Jeng; Rohit K Khosla; Mai-Thy Truong; Ann Marqueling; Joyce M C Teng Journal: JAMA Dermatol Date: 2018-11-01 Impact factor: 10.282
Authors: Joana M Mack; Bethany Verkamp; Gresham T Richter; Richard Nicholas; Kelly Stewart; Shelley E Crary Journal: Pediatr Blood Cancer Date: 2019-06-28 Impact factor: 3.167
Authors: Jennifer Hammer; Emmanuel Seront; Steven Duez; Sophie Dupont; An Van Damme; Sandra Schmitz; Claire Hoyoux; Caroline Chopinet; Philippe Clapuyt; Frank Hammer; Miikka Vikkula; Laurence M Boon Journal: Orphanet J Rare Dis Date: 2018-10-29 Impact factor: 4.123